Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Conclusion: Final Thoughts on Treatment Advances in NSCLC

August 21st 2013

Selecting a First-Line EGFR Inhibitor in NSCLC

August 21st 2013

GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

August 21st 2013

Novel Immunotherapy Combinations in NSCLC

August 21st 2013

Targeting the Immune System in Non-Small Cell Lung Cancer

August 21st 2013

Case Study: Treating KRAS-Mutant Adenocarcinoma

August 21st 2013

Case Study: Progression on ALK Inhibitors in NSCLC

August 21st 2013

Case Study: MET and ALK Targeted Therapies in NSCLC

August 21st 2013

Case Study: Second-Line Treatment of Adenocarcinoma

August 21st 2013

PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

August 21st 2013

Case Study: Mutation-Negative Patient With Adenocarcinoma

August 21st 2013

Case Study: Maintenance Therapy in Squamous NSCLC

August 21st 2013

Case Study: Treating an Elderly Patient With Squamous NSCLC

August 21st 2013

Bonnie Addario on Lung Cancer Support Groups

August 19th 2013

Bonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Dr. Brahmer on the Future of Antibodies for Lung Cancer

August 16th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.

Dr. Carbone on Immunotherapy Research in Lung Cancer

August 15th 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Dr. Vokes on Multimodality Therapy for Lung Cancer

August 14th 2013

Everett E. Vokes, MD, Giant of Cancer Care in Head and Neck from University of Chicago Medicine and Biological Sciences, discusses multimodality therapy for lung cancer.

Dr. Langer Discusses Afatinib in EGFR-Positive NSCLC

August 13th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

First-Line Necitumumab Improves Survival in Metastatic Squamous NSCLC

August 13th 2013

A phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.